Asymmetric FGF receptor dimerization: implications for FGF23 biology and drug discovery
American Journal of Physiology-Cell Physiology · 2025
DOI: 10.1152/ajpcell.01020.2024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Physiology-Cell Physiology, 2025. Verfasst von Mohammed S Razzaque und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Education, School of Medicine, The University of Texas Rio Grande Valley, Edinburg, Texas, United States. Hauptthemen laut MEDLINE: Receptors, Fibroblast Growth Factor, Drug Discovery, Fibroblast Growth Factors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: MOST | NSFC | National Natural Science Foundation of China-Zhejiang Joint Fund for the Integration of Industrialization and Informatization (NSFC-Zhejiang Join…, MOST | NSFC | National Natural Science Foundation of China-Zhejiang Joint Fund for the Integration of Industrialization and Informatization.
Abstract (Originalsprache)
Fibroblast growth factor 23 (FGF23) requires both αKlotho and heparan sulfate proteoglycans (HSPGs) as obligatory coreceptors to bind, dimerize, and activate its FGF receptors (FGFRs) in the kidney, thereby regulating mineral ion and vitamin D homeostasis. Cryogenic electron microscopy studies reveal that FGF23 signaling proceeds through an asymmetric 1:2:1:1 FGF23–FGFR–αKlotho–HS assembly. According to this structural model, αKlotho simultaneously anchors FGF23 and one FGFR chain, referred to as the primary receptor (FGFR P ), to form a 1:1:1 FGF23-FGFR P -αKlotho triplex, which boosts FGF23-FGFR P interaction. Subsequently, the HS coreceptor aids the triplex in recruiting a second FGFR chain, or secondary receptor (FGFR S ), leading to asymmetric receptor dimerization. This recruitment is driven by the interactions of FGF23 and FGFR P from the triplex with the secondary receptor, with no direct involvement from αKlotho. This model outlines the possibility of heterodimerization among the renal cognate receptors of FGF23 (namely, FGFR1c, FGFR3c, and FGFR4), which may introduce signaling diversity affecting phosphate and vitamin D regulation. In addition, it proposes that kidney-specific HS structures could cooperate with renal αKlotho to home FGF23 to renal tissues. The proposed FGF23 signaling assembly provides a framework for further investigation and may inform the development of FGF23 antagonists or partial agonists for treating disorders associated with phosphate and vitamin D dysregulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Education, School of Medicine, The University of Texas Rio Grande Valley, Edinburg, Texas, United States.
- Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, People's Republic of China.
ORCID-Profile: Mohammed S Razzaque
Förderung
- MOST | NSFC | National Natural Science Foundation of China-Zhejiang Joint Fund for the Integration of Industrialization and Informatization (NSFC-Zhejiang Join…
- MOST | NSFC | National Natural Science Foundation of China-Zhejiang Joint Fund for the Integration of Industrialization and Informatization
Zitieren
APA
Razzaque, M. S., & Mohammadi, M. (2025). Asymmetric FGF receptor dimerization: implications for FGF23 biology and drug discovery. American Journal of Physiology-Cell Physiology. https://doi.org/10.1152/ajpcell.01020.2024
Vancouver
Razzaque MS, Mohammadi M. Asymmetric FGF receptor dimerization: implications for FGF23 biology and drug discovery. American Journal of Physiology-Cell Physiology. 2025. doi:10.1152/ajpcell.01020.2024
BibTeX
@article{Razzaque2025,
author = {Razzaque, Mohammed S and Mohammadi, Moosa},
title = {Asymmetric FGF receptor dimerization: implications for FGF23 biology and drug discovery},
journal = {American Journal of Physiology-Cell Physiology},
year = {2025},
doi = {10.1152/ajpcell.01020.2024}
}
EUVIMED